MK-7123
Total Payments
$2.7M
Transactions
286
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $498,290 | 78 | 0 |
| 2019 | $1.3M | 142 | 0 |
| 2018 | $881,880 | 66 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.7M | 285 | 100.0% |
| Consulting Fee | $675.00 | 1 | 0.0% |
Payments by Type
Research
$2.7M
285 transactions
General
$675.00
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase II Study of Navarixin MK-7123 in Combination with Pembrolizumab MK-3475 in Participants with Selected Advanced,Metastatic Solid Tumors | Merck Sharp & Dohme Corporation | $2.5M | 0 |
| A Phase II Study of Navarixin (MK-7123) in Combination with Pembrolizumab (MK-3475) in Participants with Selected Advanced/Metastatic Solid Tumors | Merck Sharp & Dohme Corporation | $184,123 | 0 |
Top Doctors Receiving Payments for MK-7123
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $2.7M | 285 |
| , M.D | Diagnostic Radiology | Kendall Park, NJ | $675.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.7M
- Total Doctors 1
- Transactions 286
About MK-7123
MK-7123 is a drug associated with $2.7M in payments to 1 healthcare providers, recorded across 286 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2020. In 2020, $498,290 was paid across 78 transactions to 0 doctors.
The most common payment nature for MK-7123 is "Unspecified" ($2.7M, 100.0% of total).
MK-7123 is associated with 2 research studies, including "A Phase II Study of Navarixin MK-7123 in Combination with Pembrolizumab MK-3475 in Participants with Selected Advanced,Metastatic Solid Tumors" ($2.5M).